Source: International Business Times
Shares of Centessa Pharmaceuticals plc skyrocketed more than 44% Tuesday after the clinical-stage biotech announced it would be acquired by pharmaceutical giant Eli Lilly and Co. in a deal valued at up to $7. 8 billion, giving Lilly a promising pipeline of experimental treatments for sleep-wake disorders.
Aller á la Source
Nouvelles connexes
